Reuters: GSK’s ViiV unit adds new HIV drug to AIDS patent pool
“GlaxoSmithKline’s AIDS drugs business is to add one of its latest HIV medicines to a patent pool — cutting its future price for developing countries and pooling intellectual property rights. ViiV Healthcare, which is majority owned by the British drugmaker, said the agreement covered dolutegravir, a new antiretroviral medicine, for use in both adults and children with the human immunodeficiency virus (HIV) that causes AIDS…” (Kelland, 4/1).